Objectives: To assess, using an in vivo engraftment strategy combining bone marrow cell (BMC) transplantation and tissue cardiomyoplasty, the functional outcome of distinct vascular progenitor cell therapy (endothelial progenitor (EPC) and mesenchymal stem (MSC) cells) at distance of myocardium infarction (MI). The study was also designed to test whether scaffold mixing progenitors with unfractionated BMC could improve progenitor recruitment in the damaged myocardium. Methods: To track engrafted progenitor cells in vivo, cultured murine MSC and EPC were transduced with eGFP lentiviruses. Thirty days after cryogenical induction of MI, C57BL/6J mice were randomized to receive muscle patch placement coated or not (control group), labeled EPC or MSC mixed to the ration of 1:10, or not with unfractionated BMC. Two weeks after transplantation, cardiac function was recorded and heart sections were examined to detect GFP-labeled progenitor cells and analyze cell differentiation. Results: This study showed that either type of mono cell therapy improved angiogenesis and cell survival in the scar but only MSC exhibited the capacity to invade the scar. We found no evidence of myocardial or vascular regeneration from progenitor cells. Engraftment of the progenitors/unfractionated BMC mix increased repopulation and thickness of the scar. Conclusion: Combined therapy with unfractionated BMC and expanded MSC appeared thus promising for scar repopulation. #
Introduction
Despite improvements in medical and surgical therapy [1] , ischemic heart disease remains the leading cause of heart failure in Western countries. In recent years, there has been a growing enthusiasm for the use of blood and marrow-derived cell-based therapies to protect, repair or regenerate damaged myocardium [2, 3] . Conceptually, cell therapy for cardiovascular disease has evolved from the idea that cardiac progenitor or stem cells could regenerate injured myocardium by de novo myogenesis to a broader premise that cell therapy may help facilitate tissue repair. Such complementary aspects might include improved cardiomyocyte survival (limited apoptosis), tissue oxygenation (angiogenesis) and improvement in recovery of cellular and tissue function (positive remodeling).
We have previously developed a 3D scaffold method for cardiac tissue engineering in a mouse model of myocardial infarction, in which a muscle patch containing bone marrow cell (BMC) embedded into a 3D collagen matrix is maintained vis-à-vis the myocardial infarct area. In this model, we showed that BMC were able to migrate from the muscle patch into the infarct zone, to increase capillary density and restore cardiac function. The beneficial effect of this cell therapy on ischemic myocardium was likely due to a paracrine release of pro-angiogenic factors and cytokines, thereby facilitating cell survival, cell recruitment and angiogenesis [4] .
Bone marrow-derived subpopulations, i.e., endothelial progenitor cells (EPC) or mesenchymal stromal cells (MSC), have shown promise in regenerative medicine [5, 6] . MSC have indeed demonstrated their ability to regenerate vessels and damaged myocardium in several experimental studies [7] [8] [9] . EPC are present in the systemic circulation, increase in response to tissue ischemia, home to and incorporate into sites of neovascularization [10] . Moreover, mobilization and recruitment of EPC contributes to vasculogenesis in vivo [11] . EPC and MSC appear to be attractive cells in therapy because of their role as source of cytokines and growth factors but also because of their supposed cardiomyocyte and endothelial transdifferentiation potential [12, 13] . As stem cells reside in highly regulated microenvironments called niches [14, 15] , a recent scenario for stem cell therapy envisioned the use of a mixture of bone marrow cells with enriched purified stem cells to recreate a niche in the treated tissue.
In view of these findings, we sought to assess the fate and outcome of purified and expanded EPC and MSC on vascular and cardiac regeneration into the infarct myocardium following engraftment in a 3D collagen patch model. In addition, as environment has a crucial role in the commitment of stem cells, we compared the functional benefit of mixing unfractionated BMC with either purified progenitor cell populations on angiogenesis and myogenesis within the ischemic heart.
Materials and methods

Isolation and preparation of stem cells
Bone marrow cells (BMC)
Bone marrow cells were harvested by flushing the tibiae and femurs of C57BL/6 mice (Charles River Laboratories) with DMEM, and further purified in Ficoll Paque (Amersham Biosciences, Orsay, France).
Endothelial progenitor cells (EPC)
1 Â 10 6 /ml mononuclear cells without any further cell subpopulation enrichment procedure were plated on different culture dishes coated with fibronectin (Sigma) in endothelial basal medium (EBM2) (Clonetics Inc., San Diego, California, USA) supplemented with endothelial growth medium Single Quots and 20% FCS, and incubated at 37 8C in a 5% CO 2 humidified environment. After 24 h, unattached cells and debris were removed by washing with medium. Culture medium was changed every 5 days, and cells were characterized and used after 12 days of the primary culture.
Mesenchymal stem cells (MSC)
Mononuclear cells were resuspended and seeded at a density of 1 Â 10 6 cells/cm 2 in petri dishes and cultured in
McCoy's medium (Invitrogen) with 10% BFS and 10% horse serum. Five to seven days later the nonadherent hematopoietic cells were discarded. The adherent bone MSCs were maintained in a humidified incubator at 37 8C with 5% CO 2 in the absence of any exogenous growth factor or anchoring materials such as fibronectin or collagen. The attached cells grew and developed colonies in 15-30 days, when the colonies were subcloned and re-seeded. Five selected clones were passed more than eight times prior to their characterization and further use. These clones displayed all the same phenotypic characteristics.
Phenotype characterization of EPC and MSC
To detect the uptake of 1,1 0 -dioctadecyl-3,3,3,3 0 -tetramethylindocarbocyanine-labeled acetylated LDL (DiI-acLDL), cells were incubated with DiI-acLDL (2.5 mg/ml) (molecular probe) at 37 8C for 1 h.
MSC and EPC were characterized using immunostaining. Cells from cultures were rinsed twice with PBS and fixed immediately with 2% PFA for 10 min, permeabilized (0.2% Triton X-100, 2 min) and saturated with 5% of BSA (Sigma). Endothelial or EPC markers were used: CD31 (Pharmingen), CD34 (Immunotech Inc.), and VE-cadherin (Santa Cruz Biotechnology Inc.), leukocytes markers: CD45 (30-F11, Pharmingen), CD4 (W3/25, Serotec), CD3 (Becton Dickinson), mesenchymal stem cell markers Sca1 (D7, Becton Dickinson), cKit (Santa Cruz), Thy1 (sc9163, Santa Cruz), Endoglin (sc18893, Santa Cruz), yoyo-1 (Molecular Probes) for nucleus staining. Biotinylated secondary antibodies used were: antirabbit IgG or anti-mouse IgG (Amersham), or anti-goat IgG (Jackson ImmunoResearch Laboratories Inc). Streptavidin-FITC complex or Alexa 568 was used for immunofluorescence analysis (Molecular Probes). All primary and secondary antibodies were diluted in PBS plus 1% BSA.
Total RNAs were prepared from cultured cells in guanidinium thiocyanate buffer, and reverse transcriptionpolymerase chain reactions (RT-PCR) were carried out as previously described [16] . Negative controls without RT were prepared in parallel for each RNA sample. The list of primers used to characterize each cell type is shown in Table 1 .
Transduction of stem cells with lentivirus
Cultured EPC or MSC were transduced with SIN eGFP lentiviral vector from Moreau-Gaudry laboratory by replacing the medium with fresh medium containing viral supernatant and incubating for 3 h at 37 8C. Cells were harvested 48 h after the infection and seeded as described above. Table 1 List of primers used for EPC characterization
Transduction was repeated for each EPC culture. MSC were transduced once and retained the fluorescence during the following passages (Fig. 1C ). BMC were not GFP-transduced and were directly seeded in the patch, unlabeled.
Mice muscle patch model
All mice used were male C57BL/6J (Charles River), 9-12 weeks old and weighing 26-30 g. All mice received humane care in compliance with the European Convention on Animal Care (L358-86/609/EEC). Myocardial infarction was induced by cryoinjury as previously described [4] .
Study treatments
Mice were randomly assigned to five treatment groups (Fig. 1A) . One group underwent sham treatment (i.e., rethoracotomy and immediate closure) 30 days after MI induction. The other groups received rethoracotomy and placement of a muscle patch coated with EPC or MSC AE BMC adjunction 30 days after MI induction (Fig. 1A) . All groups were also injected with BrdU 24 h before sacrifice in order to measure the rate of cell proliferation. All mice that survived for 15 days were sacrificed.
Isolation and placement of muscle patches
The muscle patches were obtained as previously described [4] . Briefly, 30 days after MI, a 1 cm Â 1 cm patch of abdominal muscle was harvested and cupped so as to fit the left ventricular geometry and form a tank in which cells were deposited and secured ( Fig. 1C and D) .
Deposition of stem cells on muscle patch
We used 5 Â 10 6 BMC, 5 Â 10 5 eGFP/MSC and 5 Â 10 5 eGFP/EPC in their corresponding groups. These stem cells were mixed into a growth factor-deprived liquid matrix rich in collagen type 1 (200 ml, 200 mg/ml, Becton Dickinson) [4] . This mixture was then deposited within the muscle patch and the coated muscle patch was positioned on the exposed epicardium directly above the MI zone.
Hemodynamic analysis
Hemodynamic analysis was performed as previously described using a 1.4F Millar transducer (Millar Instruments, Houston, TX) [4] .
Histological analysis 2.6.1. Morphometric analysis
Infarct size was determined in a minimum of six mice in each treatment group as described previously [17] .
Immunochemistry and confocal analysis
Mice were sacrificed by lethal injection of potassium chloride. Their hearts were fixed by pressure perfusion with a 4% paraformaldehyde solution and cut perpendicularly to the longitudinal axis of the LV in the middle of the patch. These two sections were embedded in OCT compound and stored at À80 8C. To detect cell repopulation in the scar, tissue sections were incubated with popo (popo TM -3 iodide, Molecular Probes). To detect angiogenic activity, endothelial cells were stained with CD31 antibody (Pharmingen). To determine the extent of transplanted cell proliferation, specimens were immunostained with a BrdU antibody (Harlan). A minimum of 30 random digital photographs was taken at Â40 magnification for each mouse specimen analyzed. Positively stained eGFP cells or CD31-positive capillaries and BrdU positive cells were manually counted by a blinded observer with the help of Sigma Scan Plot software.
To evaluate cell differentiation, a CD31 antibody (BMA) was used for endothelial cell detection, a smooth muscle aactin antibody for smooth muscle cell detection, and an antia-cardiac sarcomeric actin (Abcam, 5C5) for myocyte detection. Slides were analyzed under a confocal microscope searching for eGFP/rhodamine double staining.
The number of transplanted cells, capillary density, and cell proliferation per square millimeter were determined and recorded.
Statistical analysis
All data were expressed as mean AE SD. All analyses were performed using appropriate software (Statview 5.1). Comparisons of continuous variables between two groups were made using one-way ANOVA and, when a statistically significant difference was observed, a two-sided paired t test. A value of p < 0.05 was considered statistically significant. 
Results
Recent evidence has shown that it is possible to improve cardiac function or perfusion or to decrease the loss of viable myocardium and with bone marrow-derived progenitor cells. To identify a source of progenitors capable of restoring damaged cardiac tissue, we engrafted EPC and MSC embedded in a muscular patch placed above the cardiac ischemic area.
Phenotype of EPC and MSCs
We used both EPC and MSC to test their vascular or cardiogenic potential in vitro and in vivo. First, the expression of genes of primitive and fully differentiated endothelial and smooth muscle cells was analyzed in both cell lines.
The surface markers of EPC were determined by immunostaining and flow cytometry analyses as previously reported. EPC were co-stained with acetylated-LDL ( Fig. 2A) . EPC expressed VEGF Receptor 2, CD31 and CD34 (data not shown). Real-time PCR amplification showed that EPC featured expression of genes reflective of endothelial lineages (VE-cadherin, Flk-1, Flt-1, angiopoietin-1 and 2, Tie-1 and 2) (Fig. 2A) . MSC expressed moderate to high level of Sca1, cKit, Thy1 while Endoglin, CD31, CD34, CD3 and CD45 were negative (data not shown and Fig. 2A) . To track engrafted cells in vivo, both EPC and MSC were infected at a low level with a lentiviral vector expressing GFP that did not alter in vitro growth rate and viability. Almost 100% of the cells expressed GFP after a single round of infection.
Myocardial infarction and mortality
Of the 119 C57BL/6 mice that underwent MI induction by cryoinjury, 12 mice died during the first 24 h (10%). Thirty days after MI, 96 C57BL/6 mice received progenitor cells embedded in the muscular patch. For this purpose, mice were randomized to five groups: the first group received 5 Â 10 5 eGFP-labeled EPC (n = 24), the second group, 5 Â 10 5 eGFP-MSC (n = 24), the third group, a mix of 5 Â 10 5 eGFPlabeled EPC and 5 Â 10 6 unlabeled BMC (n = 24) and the fourth group, a combination of 5 Â 10 5 eGFP-labeled MSC and 5 Â 10 6 unlabeled BMC (n = 24). The last group was the control (operation with uncoated patch) performed on 11 animals (Fig. 1) . After coated-patch implantation, the early mortality rate was approximately around 40%, consistent with our previous observation. The mortality did not differ significantly between the four groups.
MSC but not EPC can migrate from the implanted patch to the infarcted area
We then investigated the capacity of the progenitors to penetrate and migrate into the ischemic and scar area. In MI hearts covered with a patch containing MSC, 46.6 AE 3.1 eGFP-positive MSC/mm 2 were detected in the MI area, representing about 1.5% of the total cells of the scar. Most of eGFP-positive cells were detected in the ischemic border zone while none were found in uninjured zones. In contrast, only sporadic eGFP-positive EPC were detected in the MI area in patch plus EPC-treated mice (Table 2 and Fig. 3 ). These findings suggested that, in this model of epicardial cell deposition, only MSC but not EPC could be successfully mobilized to migrate to the MI area.
Epicardial deposition of MSC or EPC increased angiogenesis and cell survival in the scar
As formation of new blood vessels within the provisional ventricle wound matrix is known to be essential for normal healing, frozen heart sections were immunostained with anti BrdU and CD31 antibodies to evaluate respectively cell proliferation and capillary formation as markers of myocardial recovery in the different groups. Examination of the sections from mice grafted with patch plus either EPC or MSC showed a significant increase of the proliferation and of the capillary number as compared to sections from control mice ( Table 2 , p < 0.01). The proliferation and capillary density were similar in sections from both EPC-and MSC-treated mice ( Table 2 , p = NS). 
Mobilization of progenitor cells did not contribute to the regeneration of vascular endothelium, smooth muscle or cardiac tissue
Here, we analyzed whether mobilized progenitor cells can differentiate in situ to form capillary network or to regenerate cardiomyocytes using immunofluorescent techniques. In the myocardial area, a few of eGFP-positive MSC cells (less than one per MI heart) were positive for CD31 or aactin staining using confocal microscopy analysis (Fig. 4) , suggesting that transdifferentiation or fusion between transplanted and resident cells were very rare events. Moreover, no transdifferentiation into cardiomyocytes was observed as eGFP-positive MSC cells remained negative for asarcomeric actin (Fig. 4) .
Mixing total BMC with MSC increased MSC numbers in the scar, modified myocardial infarction scar tissue but did not promote MSC transdifferentiation
To determine the role of the environment on progenitor behavior, we tested whether a mixture of total BMC either with EPC or MSC could be instrumental to trigger progenitor cells to migrate and achieve tissue repair in the infarct scar.
An eGFP-MSC mix with BMC adjunction led to a higher quantity of MSC in the scar as compared with eGFP-MSC alone ( p < 0.01; Table 2 ). A mean of 286 AE 11.5 eGFP-positive MSC/mm 2 was detected in the necrotic area, representing 7% of the cells into MI area, in the group MSC plus BMC ( Table 2 , Fig. 3 ). In contrast, BMC adjunction to EPC in the patch did not induce EPC migration in the scar. We next tested whether BMC could provide a microenvironment that would contribute to MSC commitment. We failed to detect any progenitor cell that co-expressed eGFP and either endothelial or cardiac markers indicating that BMC environment did not favor MSC incorporation into neovascular structure or into cardiac tissue.
Noteworthy, BMC adjunction modified infarct scar tissue since the total cell number in the scar was significantly higher Values are expressed as mean AE SD. * p < 0.01 as compared to control group. ** p < 0.01 as compared to MSC or EPC alone-treated group. Fig. 3 . Stem cell migration to the scar. Transplanted stem cells that have migrated into the scar are detected by eGFP analysis under fluorescent confocal microscopy. The white line represents the border zone between the infarct scar and the coated muscle patch. Arrows represent cell migration from the patch to the scar. In EPC or in EPC + BMC coated muscle patch, only sporadic eGFP-positive cells were found in the scar. Better results were found in the MSC-coated muscle patch group. In the MSC + BMC coated muscle patch group, the number of eGFP-positive cells was significantly higher in the scar, p < 0.01. in the BMC plus EPC or MSC groups than in the progenitor cells alone groups ( Table 2) . One of the consequences was a significant increase in scar thickness, probably caused by an increase in cell density due to BMC invasion. However, cell proliferation and capillary density were not significantly different between the progenitors groups with or without BMC ( Table 2) .
MSC and EPC engraftment improved cardiac function
Infarct size as measured by the percentage of left ventricle necrosis was similar in all groups, control, and EPC or MSC-patch with or without BMC. This was not surprising as the cryolesion-induced MI was done 30 days before cell therapy was applied. Cardiac function as measured by dp/dt was significantly increased in all groups compared to the control group. However no significant differences were found between the four progenitor groups (Table 3 ).
Discussion
The main new findings of the study are: (1) at 2 weeks after deposition of either progenitor cells, only MSC but not EPC are able to migrate to the ischemic zone, (2) both EPC and MSC have the capacity to enhance capillary formation and cell survival in the scar but do not give rise to vascular or myocardial cells (3) combined progenitor cell with unfractionated BMC therapy results in an enhancement of MSC migration to the scar and favors scar repopulation.
Background and muscle patch cell delivery
In a precedent study, we showed the feasibility of improving cardiac function and remodeling irreversibly damaged myocardial tissue after MI by embedding BMCs in a collagen-rich matrix, applying the matrix directly to the damaged epicardium. The intramyocardial injection technique is limited by (1) the extensive mechanical trauma to cells (and consequent apoptosis) that can be caused by the syringes and needles that must be used, (2) the limited total number of cells in solution that can be injected, and (3) and the inhospitability of the scar environment to transplanted cells. Thus, in developing our epicardial deposition strategy, we have tried to offset these disadvantages by making it possible to (1) use unrestricted numbers of transplanted cells; (2) deposit cells in a trauma-free way that avoids the use of inappropriate devices and avoids immunogenic reactions; (3) place transplanted cells in a favorable environment (i.e., collagen) conducive to their survival, proliferation, and migration; and (4) use a homologous muscle patch as a reservoir in which to allow transplanted cells in the matrix to form a stronger, more adherent bond with the patch itself. We demonstrated that this combined strategy could increase capillary density, improve cardiac function and increase scar thickness. The effect on scar thickness could be related to an important cell migration, cell survival and proliferation rate. Moreover, we had found that autologous abdominal muscle patches could become easily integrated into, and in some cases even merge with, the epicardium. These advantages were offset somewhat by the tendency of the abdominal muscle patches to become thinner over time because of ischemic complications; however, this thinning was significantly less severe when the patch was coated with BMCs, presumably owing to the evident tropic and degradationinhibiting effects of the BMCs. We were not able to demonstrate any inflammatory response in the different sites of fixation. This data showed that the paracrine effect, increasing capillary density in the scar, could not be related to a secretion of growth factor by the postoperative inflammatory response [4] .
Progenitor cell differentiation
Our goal was to define the optimal cell type for myocardial revascularization in this epicardial deposition model. It has been demonstrated that, in some culture conditions, progenitor cells are able to transdifferentiate into vascular cells or cardiomyocytes [18, 19] . We isolated and cultured MSC and EPC that presented the same characteristics and properties as previously reported [20, 21] . To date, EPC and MSC have been used for cardiac regeneration [2, 9, 22] . Functional efficacy of such progenitor cells has been well documented, even if there are some controversies in their in vivo and in vitro differentiation abilities [23, 24] . However, with more than 50 mice carefully examined, we found no evidence of vascular or myocardial regeneration from immunolabeled injected progenitor cells.
Modification of infarct scar
3D engraftment of EPC and MSC has improved cardiac function although scar area was not reduced by any of the cell types. Indeed, we chose a delayed timing of cell delivery to make the protocol more clinically relevant. In a clinical perspective, such a deleterious environment remains a major step for rationalizing the progenitor use. It is also possible that this delay of 1 month after MI onset for progenitor engraftment could be a limit in the repair benefit. Nevertheless, MSC, but not EPC, were able to migrate to the infarct scar but to a limited extent (1% of the scar cellularity), limiting their functional potential in situ. Table 3 Comparison of the groups on cardiac function, hemodynamic study as measured by dp/dt max However, independent of their migration capacities, both progenitor cells induced modifications of the infarcted myocardial tissue (increased in capillary density and cell proliferation) as compared to control mice. As we did not detect any transdifferentiation into endothelial or smooth muscle cells or cardiomyocytes, the angiogenic effect and cell proliferation in the scar were probably induced via a paracrine effect of the progenitors. In vitro characterization has shown that both MSC and EPC were able to secrete growth factors, angiogenic factors and some cytokines (laboratory unpublished data) [13, 25] .
Bone marrow cell environment benefit
We investigated whether the adjunction of BMC could enhance EPC or MSC numbers in the infarct area. Mix of MSC with unfractionated BMC gave rise to larger MSC fraction in the scar than that with MSC alone. EPC did not migrate in the scar even if BMC were added. This suggests that BMC create a specific and favorable environment that facilitate and/or preserve MSC repopulation into the scar. This further emphasizes that BMC environment is crucial to ensure a proper MSC engraftment or migration to the scar but may not allow their commitment toward a vascular or myogenic phenotype. We should however point out that the increase in MSC population did not account for a better capillary formation or cell proliferation.
Conclusion
This study suggests that a combined strategy of either unfractionated or purified progenitor cell therapy with cardiomyoplasty increases capillary density, cell proliferation and repopulation into the scar even at distance of an MI event. Expanded MSC kept the capacities to invade and participate in the scar repopulation but are not directed to form vascular or cardiac cells. Our study suggests mixing BMC with MSC is critical for the success of MSC engraftment and is promising as to the use of MSC in cell therapies.
